首页> 外文期刊>Frontiers in Immunology >Induction of Antihuman C–C Chemokine Receptor Type 5 Antibodies by a Bovine Herpesvirus Type-4 Based Vector
【24h】

Induction of Antihuman C–C Chemokine Receptor Type 5 Antibodies by a Bovine Herpesvirus Type-4 Based Vector

机译:抗人生C-C趋化因子受体诱导牛疱疹病毒型载体的5型抗体

获取原文
           

摘要

Bovine herpesvirus 4 (BoHV-4) is a promising vector for the delivery and intracellular expression of recombinant antigens and can thus be considered as a new prototype vaccine formulation system. An interesting, and actively pursued, antigen in the context of human immunodeficiency virus (HIV) infection prophylaxis (and therapy) is the C–C chemokine receptor type 5 (CCR5) co-receptor, whose blockage by specific antibodies has been shown to inhibit both viral entry and cell-to-cell transmission of the virus. Building on our previous work on the BoHV-4 vector system, we have engineered and tested a replication-competent derivative of BoHV-4 (BoHV-4-CMV-hCCR5ΔTK) bearing a human CCR5 (hCCR5) expression cassette. We show here that CCR5 is indeed expressed at high levels in multiple types of BoHV-4-CMV-hCCR5ΔTK-infected cells. More importantly, two intravenous inoculations of CCR5-expressing BoHV-4 virions into rabbits led to the production of anti-CCR5 antibodies capable of reacting with the CCR5 receptor exposed on the surface of HEK293T cells through specific recognition of the amino-terminal region (aa 14–34) of the protein. Given the growing interest for anti-CCR5 immunization as an HIV control strategy and the many advantages of virus-based immunogen formulations (especially for poorly immunogenic or self-antigens), the results reported in this study provide preliminary validation of BoHV-4 as a safe viral vector suitable for CCR5 vaccination.
机译:牛Herpesvirus 4(BoHv-4)是重组抗原的递送和细胞内表达的有希望的载体,因此可以被认为是新的原型疫苗制剂体系。在人类免疫缺陷病毒(HIV)感染预防(和治疗)的背景下是有趣的,积极的追求,抗原是C-C趋化因子受体类型5(CCR5)共同受体,其通过特异性抗体阻断已显示抑制病毒的病毒进入和细胞对细胞传输。在我们以前的BoHV-4向量系统上建立工作,我们已经设计并测试了携带人类CCR5(HCCR5)表达盒的BoHV-4(BoHV-4-CMV-HCCR5ΔTK)的复制主管衍生物。在此显示CCR5确实在多种类型的BoHV-4-CMV-HCCR5ΔTK感染细胞中以高水平表达。更重要的是,将CCR5表达的BOHV-4病毒粒的两个静脉内接种成兔导致了能够通过氨基末端区域的特异性识别(AA 14-34)蛋白质。鉴于抗CCR5免疫的兴趣日益增长为HIV控制策略以及病毒的免疫原制剂的许多优点(特别是对于免疫原性或自我抗原的较差或自我抗原),本研究报告的结果提供了BoHV-4的初步验证安全的病毒载体适用于CCR5疫苗接种。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号